Besifloxacin

DB06771ApprovedSmall moleculeAnti-Bacterial Agents Quinolone Antimicrobial

Besifloxacin is a fluoroquinolone antibiotic agent used for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

Mechanism: Besifloxacin is a bactericidal fluroquinolone-type antibiotic that inhibits bacterial enzymes, DNA gyrase and topoisomerase IV. By inhibiting DNA gyrase, DNA replication, transcription, and repair is impaired. By inhibiting topoisomerase IV, decatenation during cell devision is impaired. Inhibiting these two targets also slows down development of resistance.
Curator reviewed
Primary indication: Treatment of bacterial conjunctivitis.Curator reviewed · 1 structured indication
Formula / weight: C₁₉H₂₁ClFN₃O₃ · 393.84 g/mol (avg)
First approval: Canada, 2009 · United States, 2009
Code names: ISV-403
Brand names: Besivance

Resolves to

Compound

UNIIBFE2NBZ7NXCAS141388-76-3ChEMBLCHEMBL1201760ChEBI135622PubChem10178705KEGGD08872

Clinical / RWD

RxNorm819911ATCS01AE08

Structure

InChIKeyQFFGVLORLPOAEC-SNVBAGLBSA-NSMILESN[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O

Targets

P43702parCP72525parCP43700gyrAP72524gyrAP0A0K8gyrBP20831gyrA

What you can answer from here — as of September 11, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

421Drug interactionsStructured to mechanism, not free text

17Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

12Marketed productsAcross 6 countries and 6 labellers

1ATC codeIncluding every combination product, plus 19 drug categories

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Besifloxacin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In